ENGLEWOOD, Colo., Nov. 14,
2019 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI),
an innovative medical technology company specializing in the
manufacture and sale of non-invasive medical devices for pain
management, stroke rehabilitation, cardiac monitoring and
neurological diagnostics, today announced it has been ranked
18th in revenue growth among all medical device
companies in the U.S. and Canada
on Deloitte's 2019 Technology Fast 500. Zynex was ranked
488th for revenue growth between 2015 and 2018 across
all companies in North America. Zynex's revenues grew 174%
over that period, with 2018 revenue reaching $31.9 million. The company estimates 2019
revenue between $43.6 and
$44.1 million. The 2019 Deloitte
Technology Fast 500 list can be found at www.fast500.com.
"It is an honor to be recognized this year by Deloitte's 2019
Technology Fast 500 for revenue growth," said Thomas Sangaard, CEO
and founder of Zynex Inc. "This award truly reflects the
strong commitment of our Zynex team and gives me an opportunity to
thank everyone here for their dedication and hard work. We
appreciate this award and look forward to continued revenue growth
in the years ahead."
About Deloitte's 2019 Technology Fast 500™
Now in its 25th year, Deloitte's Technology Fast 500 provides a
ranking of the fastest-growing technology, media,
telecommunications, life sciences, and energy tech companies—both
public and private—in North
America. Technology Fast 500 award winners are selected
based on percentage fiscal year revenue growth from 2015 to
2018.
In order to be eligible for Technology Fast 500 recognition,
companies must own proprietary intellectual property or technology
that is sold to customers in products that contribute to a
majority of the company's operating revenues. Companies must have
base-year operating revenues of at least $50,000, and current-year operating revenues of
at least $5 million. Additionally,
companies must be in business for a minimum of four years and be
headquartered within North
America.
ABOUT ZYNEX
Zynex, founded in 1996, markets and sells its own design of
electrotherapy medical devices used for pain management and
rehabilitation; and the company's proprietary NeuroMove device
designed to help recovery of stroke and spinal cord injury
patients. Zynex is also developing a new blood volume monitor for
use in hospitals and surgery centers.
For additional information, please visit: zynex.com.
Safe Harbor Statement
Certain statements in this release are "forward-looking" or
projections and as such are subject to numerous risks and
uncertainties. The company makes no express or implied
representation or warranty as to the completeness of this
information or, in the case of projections, as to their
attainability or the accuracy and completeness of the assumptions
from which they are derived. Actual results may vary significantly
from the results expressed or implied in such statements. Factors
that could cause actual results to materially differ from
forward-looking statements include, but are not limited to, the
need to obtain FDA clearance and CE marking of new products, the
acceptance of new products as well as existing products by doctors
and hospitals, larger competitors with greater financial resources,
the need to keep pace with technological changes, our dependence on
the reimbursement for our products from health insurance companies,
our dependence on third party manufacturers to produce our goods on
time and to our specifications, implementation of our sales
strategy including a strong direct sales force and other risks
described in our filings with the Securities and Exchange
Commission including the "Risk Factors" section of our Annual
Report on Form 10-K for the year ended December 31,
2018 as well as Forms 10-Q, 8-K and 8-K/A, press releases and
the Company's website.
INVESTOR RELATIONS CONTACT:
Amato and Partners, LLC
100 Park Avenue, 16th Floor
New York, NY 10017
(212) 430-0360
admin@amatoandpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/zynex-ranked-18th-in-revenue-growth-among-medical-device-companies-300958318.html
SOURCE Zynex